The objective of the study reported in this conference poster was to estimate mortality risks following a WHO 3/4 event according to diagnosis in individuals starting triple drug antiretroviral therapy (ART) in Africa. WHO stage 3/4 events are often used to determine success/failure of ART in middle/low-income settings where access to laboratory measurements is limited. The trial design; patients, follow-up and data; methods, WHO 3/4 events after ART initiation; risk of death in weeks 0-36 on ART, risk of death after 36 weeks on ART; estimated causal risks of death after a WHO 3/4 event after 36 weeks on ART; and conclusions are presented.
Kityo, C.; Ford, D.; Walker, A.S.; Hakim, J.; Munderi, P.; Lutwama, F.; Ssali, F.; Reid, A.; Grosskurth, H.; Gibb, D.M.; Gilks, C.F.; Babiker, Ag. Effect of WHO stage 3/4 events after ART initiation on survival of HIV-infected African adults in the DART trial. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009. (2009) 1 pp.